AGA recommends early use of biologics in patients with moderate-to-severe Crohn's disease

https://www.eurekalert.org/pub_releases/2021-05/aga-are052721.php

 

News Release 27-May-2021
American Gastroenterological Association

 

Crohn's disease, a type of inflammatory bowel disease (IBD) that causes inflammation (pain and swelling) in the gastrointestinal tract, can cause daily health problems, frequent hospitalizations and surgery when not adequately controlled. While there is no cure for Crohn's disease, there are treatments that can help patients live a symptom-free life.

After a detailed review of available literature, the American Gastroenterological Association (AGA) has released new clinical guidelines outlining the benefits and risks of each drug currently available to Crohn's patients. Based on this research, AGA recommends the early introduction of biologics for patients experiencing luminal and fistulizing Crohn's disease rather than waiting until other treatments fail. These guidelines are published in Gastroenterology, AGA's official journal.



•••••